BCM
LGND icon

Bridgeway Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Bridgeway Capital Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-8,496
Closed -$605K – 1347
2019
Q2 		$605K Sell
8,496
-801
-9% -$59K 0.01% 915
2019
Q1 		$729K Buy
+9,297
New +$704K 0.01% 876

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Bridgeway Capital Management's LGND Position: Q3 2019 in Review

Bridgeway Capital Management sold out of Ligand Pharmaceuticals (LGND) in Q3 2019, closing a stake of 8,496 shares — an estimated $605K sold.

Bridgeway Capital Management first reported a position in LGND in Q1 2019 and held it in 2 quarters. The position peaked at $729K in Q1 2019. 275 funds tracked by Wall St. Rank hold LGND as of Q3 2019.

  • Bridgeway Capital Management reported no remaining Ligand Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Bridgeway Capital Management sold 8,496 Ligand Pharmaceuticals shares in Q3 2019, an estimated $605K.
  • Bridgeway Capital Management first reported a position in Ligand Pharmaceuticals in Q1 2019 and held it in 2 quarters.
  • Bridgeway Capital Management's Ligand Pharmaceuticals position peaked at $729K in Q1 2019.
  • 275 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2019.

Based on Bridgeway Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.